AMPH vs ASRT Valuation Comparison 2026 — Intrinsic Value Analysis

Quick Summary — AMPH scores higher on quality with 10.0/10 vs ASRT's 5.4/10. AMPH trades at $18.45 while ASRT trades at $23.45. Both analyzed daily using SEC EDGAR data across 13 institutional models.

AMPH

Drug Manufacturers - Specialty & Generic

Amphastar Pharmaceuticals, Inc.

Quality

10.0

out of 10

Value Trap

12

SAFE

Price

$18.45

Last close

Models

13/13

Active

VS

ASRT

Drug Manufacturers - Specialty & Generic

Assertio Holdings, Inc.

Quality

5.4

out of 10

Value Trap

24

SAFE

Price

$23.45

Last close

Models

9/13

Active

AMPH

Bayesian DCF sees +125.3% upside

Limited to 2/13 visible models

ASRT

Bayesian DCF sees +113.2% upside

Limited to 2/13 visible models

AMPH vs ASRT — Fair Value Comparison

AMPH

ASRT

Market Price Model 1 Model 2

Model-by-Model Comparison

Model	Type	AMPH Fair Value	AMPH Upside	ASRT Fair Value	ASRT Upside
Bayesian DCF	Intrinsic	$41.58	+125.3%	$50.00	+113.2%
Earnings Power Value	Intrinsic	$13.90	-24.7%	—	—
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$33.24	+80.2%	$5.55	-69.9%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

AMPH vs ASRT — Which Stock Is More Undervalued in 2026?

AMPH scores higher with a 10.0/10 quality rating vs ASRT's 5.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

How Do AMPH and ASRT Valuations Compare?

At $18.45, AMPH trades +125.3% below its Bayesian DCF fair value of $41.58, while ASRT at $23.45 trades +113.2% below its estimate of $50.00. AMPH shows a wider gap between price and intrinsic value.

Quality of Company: AMPH vs ASRT

AMPH earns a Quality of Company score of 10.0/10 compared to ASRT's 5.4/10. This is a significant quality gap — the higher-scoring company demonstrates materially stronger fundamentals across profitability, growth consistency, and balance sheet health. The QOC score synthesizes 32 signals spanning profitability margins, revenue growth, free cash flow, capital allocation, and leverage.

Value Trap Risk: AMPH vs ASRT

AMPH carries a SAFE value trap risk (12/100) while ASRT shows SAFE risk (24/100). Both companies show manageable value trap risk, suggesting their current valuations are not artificially depressed by fundamental deterioration.

Both in Drug Manufacturers - Specialty & Generic

Both AMPH and ASRT operate in Drug Manufacturers - Specialty & Generic, which has 79 stocks tracked by CirclFi. Same-industry comparisons provide the most direct insight into relative valuation since both companies face similar regulatory environments, market dynamics, and competitive pressures. Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN), and ensemble methods (CUCE).

2 of 13 MODELS UNLOCKED

You’re comparing 2 models. 11 more have an opinion.

11 hidden models compare AMPH vs ASRT differently — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more. Some may disagree with the 2 you see above.

11 additional fair values per stock Full confidence breakdown Live terminal — 5,000+ stocks

Bloomberg Terminal: ~$2,000/mo · FactSet: ~$1,000/mo · CirclFi: $0.90/day

See All 13 Models — $0.90/day

We don’t predict prices. We show you what 13 independent mathematical frameworks say a stock is worth — and let you decide.

AMPH

View Full Amphastar Pharmaceuticals, Inc. Analysis →

ASRT

View Full Assertio Holdings, Inc. Analysis →

See all Drug Manufacturers - Specialty & Generic stocks →